Cardiogenic Shock Updates

Cardiogenic shock is a life-threatening syndrome caused by primary cardiac dysfunction resulting in inadequate cardiac output, tissue hypoperfusion, and progressive end-organ injury. Despite advances in reperfusion, critical care, vasoactive therapy, and temporary mechanical circulatory support, cardiogenic shock remains associated with high mortality and requires rapid recognition, structured triage, and coordinated multidisciplinary management.

This CME/CE activity provides an evidence-based update on contemporary cardiogenic shock care, with emphasis on the shift from reactive rescue therapy to early recognition, standardized staging, invasive hemodynamic assessment, shock-team activation, and phenotype-guided treatment. Learners will review how clinical signs, lactate, renal and hepatic function, blood pressure, cardiac index, filling pressures, pulmonary artery catheter data, and SCAI shock stages can support decisions regarding escalation, stabilization, transfer, and de-escalation.

The program also examines evolving evidence on pharmacologic and device-based support. Core topics include norepinephrine as a commonly preferred initial vasopressor when hypotension threatens perfusion, selective use of inotropes such as dobutamine or milrinone based on cardiac output and vascular tone, early coronary revascularization in infarct-related shock, and careful patient selection for temporary mechanical circulatory support. The activity contrasts with data from ECLS-SHOCK, which did not show a routine survival benefit with early ECLS in AMI-related shock and increased complications, with DanGer Shock, where a microaxial flow pump reduced 180-day mortality in selected STEMI-related shock patients but increased device-related adverse events.

By integrating recent ACC guidance, ESC ACS recommendations, and contemporary trial evidence, this activity prepares clinicians to move beyond a one-size-fits-all approach. Participants will learn how to match therapy intensity to shock severity and phenotype, identify patients who may benefit from transfer to advanced centers, recognize the risks of bleeding, limb ischemia, hemolysis, renal replacement therapy, and infection, and apply serial reassessment to improve competence, performance, and patient outcomes.

Educational Objectives

After completing this activity, learners will be able to:

• Recognize cardiogenic shock early using clinical assessment, laboratory markers, hemodynamic profiling, and standardized staging frameworks such as SCAI shock stages.
• Compare contemporary pharmacologic, revascularization, and temporary mechanical circulatory support strategies for cardiogenic shock, including their benefits, limitations, and adverse-event risks.
• Apply a multidisciplinary, phenotype-guided approach to escalation, transfer, stabilization, serial reassessment, and de-escalation of cardiogenic shock therapy.

Who Should Do This Course?

• Cardiologists and interventional cardiologists involved in acute coronary syndrome and shock management.
• Heart failure specialists and advanced heart failure teams caring for patients with acute decompensation or shock.
• Critical care physicians, emergency medicine physicians, and hospitalists managing undifferentiated shock or cardiac ICU patients.
• Cardiac surgeons, intensivists, and shock-team members involved in temporary mechanical circulatory support decisions.
• Nurse practitioners, registered nurses, physician associates/assistants, pharmacists, perfusionists, and allied health professionals supporting shock care pathways.

Did You Know?

• The 2025 ACC Concise Clinical Guidance emphasizes a one-hour and 24-hour roadmap for cardiogenic shock management, including early evaluation, shock-team activation, stabilization, and reassessment.
• The ESC 2023 ACS guidance reinforces early invasive management and revascularization strategies for acute coronary syndrome patients, including those complicated by shock.
• ECLS-SHOCK found no reduction in 30-day mortality with routine early extracorporeal life support in AMI-related cardiogenic shock and reported higher bleeding and vascular complications.
• DanGer Shock showed lower 180-day mortality with a microaxial flow pump in selected STEMI-related cardiogenic shock patients, but device use increased major adverse-event risk.
• Shock severity, hemodynamic phenotype, and end-organ injury trajectory are more useful for therapy selection than blood pressure alone.

The estimated time to complete this activity is 30mins.